• CGP 78608 Hydrochloride as an NMDA Antagonist

  2026-10-20

  CGP 78608 hydrochloride is described as a selective NMDA antagonist whose main interpretive value is as a mechanistic probe of NMDA receptor modulation. The receptor-level action can be connected conceptually to glutamatergic signaling, excitotoxicity studies, and neuroprotection readouts, but the supplied material description does not establish potency, target engagement, or protective performance in a particular model.

• Diminazene Aceturate and Sepsis Cardiomyopathy

  2026-10-19

  A literature-focused analysis of a mouse study linking pharmacological ACE2 activation by diminazene aceturate with improved sepsis-induced cardiomyopathy. The article separates reported findings from mechanistic interpretation, explains the study’s complementary pharmacological comparisons and cardiac, inflammatory, oxidative, apoptotic, and mitochondrial readouts, and emphasizes limits involving target selectivity, missing effect sizes, model specificity, and product provenance.

• Acetaminophen: Mechanism and Evidence Boundaries

  2026-10-18

  The APExBIO listing identifies acetaminophen, or paracetamol, as a high-purity small molecule described as a selective COX-2 inhibitor and links it to prostaglandin biology, oxidative stress, cell viability, hepatotoxicity research, and ferroptosis-associated observations. Because no identity-matched primary paper is available, these claims support a conceptual scope rather than a validated potency, causal mechanism, or translational conclusion.

• 25 mM dNTP Mixture: Evidence and Scope

  2026-10-17

  APExBIO describes SKU K1042 as an equimolar aqueous mixture of dATP, dCTP, dGTP, and dTTP, each at 25 mM. Its documented role is as a DNA synthesis reagent and DNA polymerase substrate, but the product information provides no identity-matched research outcomes, comparative performance data, enzyme-specific measurements, or assay-validation evidence.

• Semicarbazide Hydrochloride: Evidence and Scope

  2026-10-16

  APExBIO identifies semicarbazide hydrochloride, also called hydrazinecarboxamide hydrochloride, as a research-use biochemical reagent associated broadly with protein modification and detection. The available product information defines identity and selected physicochemical specifications but does not establish a product-specific mechanism, assay performance, or independent biological findings.

• Closantel Sodium: What the Product Record Supports

  2026-10-16

  APExBIO identifies Closantel Sodium as a sodium-salt small molecule claimed to inhibit the KinA/Spo0F two-component signaling system, with a reported IC50 of 3.8 μM. The record supports a target-level research hypothesis, but not independent conclusions about bacterial killing, spectrum, selectivity, clinical utility, or comparative efficacy.

• TP-3654: What the Available Evidence Supports

  2026-10-15

  The cited APExBIO listing identifies TP-3654 by the commercial designation and SKU BA6395, but the available product information does not document a chemical identity, molecular target, mechanism, assay principle, or performance result. Accordingly, TP-3654 can be discussed here only as an incompletely characterized commercial product, not as a validated research reagent or mechanistically established compound.

• Lisinopril Dihydrate: Evidence and Mechanism

  2026-10-15

  APExBIO identifies lisinopril dihydrate as a commercially available dihydrate form of lisinopril and an ACE inhibitor with a reported IC50 of 4.7 nM. The product description supports a mechanistic overview of ACE inhibition and its stated downstream physiological associations, but no identity-matched research paper, model-specific outcome, comparator, or independent validation is available here.

• Ionomycin Calcium Salt: Mechanism and Evidence

  2026-10-14

  APExBIO describes Ionomycin calcium salt (SKU B5165) as a calcium ionophore that raises intracellular Ca2+ through membrane transport, mobilization of regulated calcium pools, and extracellular calcium influx. The same product description associates calcium perturbation with protein synthesis and secretion in nonhuman cellular models and with apoptosis-related and tumor-growth readouts in HT1376 bladder cancer models. Because no identity-matched paper, DOI, sample sizes, effect estimates, or uncertainty measures are available here, these claims should be treated as product documentation rather than independently verifiable evidence for the specific material.

• TVB-3664: Evidence and Scope of the Listing

  2026-10-14

  The available APExBIO listing identifies TVB-3664 by name and SKU BA7718, but provides no product description, molecular identity, mechanism, assay readout, or identity-matched research evidence. Accordingly, the product can be discussed only as an incompletely characterized catalog entry, not as a validated reagent or mechanistic probe.

• CIP2A, PKM2 and Oxidative Metabolism in NSCLC

  2026-10-13

  The cited Cell Discovery study examines how CIP2A may shift NSCLC metabolism toward oxidative phosphorylation through PKM2 tetramerization. Its findings support a mechanistic model in cancer-cell and mouse studies, but do not establish clinical efficacy or a direct connection to Carboplatin.

• How Near-Death Stress May Seed Metastasis

  2026-10-13

  Conod, Silvano, and Ruiz i Altaba report that human colon cancer cells surviving an impending-death state can acquire stable prometastatic identities called PAMEs. Their findings connect endoplasmic-reticulum stress, reprogramming, and cytokine-mediated interactions with metastatic behavior, while leaving important questions about human applicability and treatment-related risk unresolved.

• What ALOX5 Evidence Shows in CRSwNP

  2026-10-12

  Huang et al. associate ALOX5 with ferroptosis-related epithelial barrier dysfunction in chronic rhinosinusitis with nasal polyps, but the study does not by itself establish clinical diagnostic utility or a complete causal pathway. Its Western blot and tissue-validation findings support biological plausibility, while the absence of documented head-to-head assay comparisons limits conclusions about any particular chemiluminescent detection system, including the SuperSignal ECL Chemiluminescent Substrate Detection Kit.

• Carboplatin Resistance and the IGF2BP3–FZD1/7 Axis

  2026-10-12

  A source-grounded overview of preclinical evidence linking IGF2BP3, FZD1/7 signaling, cancer stem-like properties, and carboplatin resistance in triple-negative breast cancer, with emphasis on evidence strength and limits of translation.

• Prevotella copri and Breast Cancer: What Was Shown

  2026-10-11

  The cited Gut Microbes study examined whether Prevotella copri may connect gut-microbiota changes with breast-cancer progression through depletion of indole-3-pyruvic acid and altered UHRF1–AMPK signaling. Its findings support a biologically plausible, but not yet clinically established, microbiome–metabolite–tumor progression model.

8642 records 1/577 page Next 12345 下5页 Last page